SCHEMBL4253283

SCHEMBL4253283

CCC(C(=O)NC(CC(=O)OC(C)(C)C)C(=O)CF)c1ccnn(Cc2cccc(OC)c2)c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 1/20 0.38
PKM P14618 4/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
PTGER4 P35408 1/20 0.37
CASP1 P29466 1/20 0.36
CASP3 P42574 1/20 0.36
CASP7 P55210 1/20 0.36
CASP8 Q14790 1/20 0.36
FPR1 P21462 1/20 0.36
FPR3 P25089 1/20 0.36
FPR2 P25090 1/20 0.36
MAPT P10636 3/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HCAR3 P49019 1/20 0.35
NPBWR1 P48145 1/20 0.34
THRB P10828 1/20 0.34
SLC16A3 O15427 1/20 0.34
SLC16A1 P53985 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4256524 0.90 CTSB (0.37) CASP1CASP3CASP7CASP8FPR2
SCHEMBL4252752 0.90 NPBWR1 (0.33) PTGER4CASP1CASP3CASP7CASP8
SCHEMBL4250363 0.90 CTSL (0.37) PKMGAACASP3MAPTMEN1
SCHEMBL4257238 0.90 PKM (0.41) PKMALDH1A1GAAPTGER4CASP1
SCHEMBL13608163 0.90 PKM (0.41) PKMALDH1A1GAAPTGER4CASP1
SCHEMBL4258250 0.90 CASP3 (0.38) CASP1CASP3CASP7CASP8MEN1
SCHEMBL4251514 0.89 NPBWR1 (0.40) ALDH1A1PTGER4MAPTMEN1KMT2A
SCHEMBL4255975 0.88 CTSB (0.37) GAACASP1CASP3CASP7CASP8
SCHEMBL4253900 0.83 LMNA (0.36) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL4249573 0.82 NPBWR1 (0.38) MAPTNPBWR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291959-A1 CASPASE INHIBITORS BASED OF PYRIDAZINONE SCAFFOLD LG LIFE SCIENCES LTD. (KR) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291959-A1 CASPASE INHIBITORS BASED OF PYRIDAZINONE SCAFFOLD CASP1, CASP2, CASP5 CACNA1B 2880/4885PKM 1333/4885ALDH1A1 3705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.